[go: up one dir, main page]

TR200201446T2 - 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as a CETP inhibitor - Google Patents

4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as a CETP inhibitor

Info

Publication number
TR200201446T2
TR200201446T2 TR2002/01446T TR200201446T TR200201446T2 TR 200201446 T2 TR200201446 T2 TR 200201446T2 TR 2002/01446 T TR2002/01446 T TR 2002/01446T TR 200201446 T TR200201446 T TR 200201446T TR 200201446 T2 TR200201446 T2 TR 200201446T2
Authority
TR
Turkey
Prior art keywords
carboxyamino
tetrahydroquinoline
ethyl
crystal
cetp inhibitor
Prior art date
Application number
TR2002/01446T
Other languages
Turkish (tr)
Inventor
John Meldrum Allen Douglas
Anthony Appleton Troy
Robinson Brostrom Lyle
Lawrence Tickner Derek
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of TR200201446T2 publication Critical patent/TR200201446T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cephalosporin Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

Formül I'in bir CETP önleyicisinin kristalin biçimleri, kristallerin yapim yöntemleri, kristalleri ve farmasötik bilesikleri içeren kristallerin kullanilis yöntemleri anlatilmaktadir. Formül (I)Crystalline forms of a CETP inhibitor of Formula I, methods of making crystals, methods of using crystals containing crystals and pharmaceutical compounds are described. Formula (I)

TR2002/01446T 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as a CETP inhibitor TR200201446T2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16805199P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
TR200201446T2 true TR200201446T2 (en) 2002-11-21

Family

ID=22609901

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/01446T TR200201446T2 (en) 1999-11-30 2000-11-14 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as a CETP inhibitor

Country Status (28)

Country Link
EP (1) EP1246804A1 (en)
JP (1) JP2003515592A (en)
KR (1) KR20020058057A (en)
CN (1) CN1402711A (en)
AP (1) AP2002002531A0 (en)
AU (1) AU1048801A (en)
BG (1) BG106854A (en)
BR (1) BR0015836A (en)
CA (1) CA2392979A1 (en)
CO (1) CO5271716A1 (en)
EA (1) EA200200510A1 (en)
EC (1) ECSP003792A (en)
EE (1) EE200200277A (en)
GT (1) GT200000199A (en)
HU (1) HUP0203521A2 (en)
IL (1) IL149097A0 (en)
IS (1) IS6338A (en)
MA (1) MA26845A1 (en)
MX (1) MXPA02005354A (en)
NO (1) NO20022558D0 (en)
OA (1) OA12099A (en)
PA (1) PA8506301A1 (en)
PE (1) PE20010904A1 (en)
PL (1) PL355892A1 (en)
TN (1) TNSN00231A1 (en)
TR (1) TR200201446T2 (en)
UY (1) UY26454A1 (en)
WO (1) WO2001040190A1 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
WO2003000295A2 (en) * 2001-06-21 2003-01-03 Pfizer Products Inc. Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors
GT200200170A (en) * 2001-09-28 2003-05-23 PREPARATION OF INHIBITOR OF CETP ANHIDRO
WO2003063822A2 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
ATE395044T1 (en) 2002-02-01 2008-05-15 Pfizer Prod Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHIC DISPERSIONS OF ACTIVE INGREDIENTS AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
EP1920766B1 (en) * 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
RU2293078C2 (en) 2002-08-30 2007-02-10 Джапан Тобакко Инк. Dibenzylamine compounds, pharmaceutical composition and therapeutic or prophylactic agent based on thereof, method for treatment or prophylaxis of hyperlipidemia or arteriosclerosis
CA2500582A1 (en) 2002-10-04 2004-04-22 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
ATE461700T1 (en) 2002-12-20 2010-04-15 Pfizer Prod Inc DOSAGE FORM CONTAINING A CETP INHIBITOR AND A HMG-COA REDUCTASE INHIBITOR
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2004222436A1 (en) 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
EP1622872A1 (en) * 2003-03-28 2006-02-08 Pfizer Products Inc. 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity
ATE540671T1 (en) 2003-08-04 2012-01-15 Bend Res Inc PHARMACEUTICAL COMPOSITIONS OF AMORPHOUS DRUG ADSORBATES AND LIPOPHILIC MICROPHASE-FORMING MATERIALS
HRP20090581T1 (en) 2003-10-08 2009-12-31 Eli Lilly And Company COMPOUNDS AND PROCEDURES FOR THE TREATMENT OF DISLIPIDEMIA
CN1942428A (en) * 2004-04-13 2007-04-04 默克公司 CETP inhibitors
MXPA06014716A (en) * 2004-06-24 2007-03-12 Lilly Co Eli Compounds and methods for treating dyslipidemia.
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
WO2006033004A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds as cetp inhibitors
WO2006091674A1 (en) 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (en) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Method for inhibiting lipid absorption and lipid absorption inhibitor
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
EP2134169A2 (en) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Combination of metformin r-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications
US20110243940A1 (en) 2008-12-16 2011-10-06 Schering Corporation Bicyclic pyranone derivatives and methods of use thereof
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
AR077208A1 (en) 2009-06-30 2011-08-10 Lilly Co Eli ACID DERIVATIVES TRANS-4 - [[(5S) -5 - [[[3,5-BIS (TRIFLUOROMETIL) PHENYLE] METHYL] (2-METHYL-2H-TETRAZOL-5-IL) AMINO) -2,3, 4,5-TETRAHIDRO-7,9-DIMETIL-1H-1-BENZAZEPIN-1-IL) METHYL) -CYCLHEXANCARBOXYL AND ITS CRYSTALLINE FORMS, PHARMACEUTICAL COMPOSITIONS THAT UNDERSTAND IT, ITS USE TO PREPARE A MEDICAM
PT3174995T (en) 2014-07-30 2020-10-15 Hoffmann La Roche Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
WO1998033775A1 (en) * 1997-02-03 1998-08-06 American Home Products Corporation 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines

Also Published As

Publication number Publication date
IL149097A0 (en) 2002-11-10
BR0015836A (en) 2002-08-06
HUP0203521A2 (en) 2003-02-28
PE20010904A1 (en) 2001-09-10
JP2003515592A (en) 2003-05-07
CA2392979A1 (en) 2001-06-07
PA8506301A1 (en) 2002-08-26
BG106854A (en) 2002-12-29
ECSP003792A (en) 2002-04-23
WO2001040190A1 (en) 2001-06-07
KR20020058057A (en) 2002-07-12
CN1402711A (en) 2003-03-12
EP1246804A1 (en) 2002-10-09
UY26454A1 (en) 2001-07-31
MA26845A1 (en) 2004-12-20
EE200200277A (en) 2003-10-15
MXPA02005354A (en) 2002-12-11
OA12099A (en) 2006-05-04
GT200000199A (en) 2002-05-23
NO20022558L (en) 2002-05-29
PL355892A1 (en) 2004-05-31
IS6338A (en) 2002-04-12
AU1048801A (en) 2001-06-12
EA200200510A1 (en) 2002-10-31
TNSN00231A1 (en) 2002-05-30
AP2002002531A0 (en) 2002-06-30
CO5271716A1 (en) 2003-04-30
NO20022558D0 (en) 2002-05-29

Similar Documents

Publication Publication Date Title
TR200201446T2 (en) 4-carboxyamino-2-ethyl-1,2,3,4-tetrahydroquinoline crystal as a CETP inhibitor
MY108885A (en) Heterocyclic-cyclic amine derivatives.
TR199800924T2 (en) Quinoline t�revleri.
DE69722027D1 (en) CRYSTALS OF BENZIMIDAZOLE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
YU49312B (en) CRYSTAL HYDRATE DERIVATIVES OF 3,4,4-TRISUPSTITUTED - PEPERIDINYL-N-ALKYL CARBOXYLATES, THEIR INTERMEDIATES AND THE PROCEDURE FOR THE PREPARATION
AP9901442A0 (en) 4-(2-Keto-1-benzimidazolinyl) piperidine compounds as orl1-receptor agonists.
ATE323717T1 (en) PIPERAZINE-4-PHENYL DERIVATIVES AS INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND MDM2
TR200800474T2 (en) Process for the preparation of intermediates of fluorfenicol.
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
MX9700557A (en) DIHYDROBENZOFURANES.
TR200002605T2 (en) Halogenated amidino amino acid derivatives useful as nitric oxide synthase inhibitors
TR200100700T2 (en) Crystalline forms of EtO2C - CH2- (R) Cgl-Aze-Pab-OH
TR199801513A2 (en) N- (4-Trifluoromethylphenyl) - 5- methyl-isoxazole-4-carboxamide crystal form.
UY24802A1 (en) NEW COMPOUNDS
DK0689549T3 (en) New urea derivatives, their preparation and use
TR200201128T2 (en) Tetrahydrothiopyraniphalazinone derivatives as PDE4 inhibitors.
TR200001909T2 (en) Matrix metalloprosthesis inhibitors.
DE69629770D1 (en) NONLINEAR CRYSTALS AND THEIR USE
TR200402776T4 (en) Hydrates of the neuraminic acid compound and their crystal forms.
DE60036558D1 (en) PHTHALAZINONE DERIVATIVES AS PDE 4 HEMMER
MD1744F2 (en) Clavulanic acid salts and process for obtaining them
HRP950437A2 (en) N-substituted azabicycloheptane derivatives, their production and use
NO994303L (en) Crystalline hydrated sodium salt of (E) -4,6-dichloro-3- (2-oxo-1-phenylpyrrolidin-3-ylidenomethyl) -1H-indole-2-carboxylic acid
TR200001122T2 (en) Biphenyl derivatives as pharmaceuticals.
NZ504741A (en) Thermodynamically stable form of (R)-3-[ [(4-fluorophenyl) sulphonyl]amino] -1,2,3,4- tetrahydro -9H-carbazole -9-propanoic acid (ramatroban)